PHILADELPHIA, Oct. 31, 2025 (GLOBE NEWSWIRE) --

Avantor, Inc. (NYSE: AVTR):

Grabar Law Office is investigating claims on behalf of shareholders of Avantor, Inc. (NYSE: AVTR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Avantor, Inc. (NYSE: AVTR), shares prior to March 5, 2024 and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased or otherwise acquired Avantor securities between March 5, 2024, and October 28, 2025, you can participate in the class action. Please visit https://grabarlaw.com/the-latest/avantor-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

WHY? As alleged in a recently filed underlying securities fraud class action complaint, Avantor, Inc. (NYSE: AVTR), through certain of its officers, made materially false and misleading statements materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Avantor’s competitive positioning was weaker than Defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, Defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

WHAT YOU CAN DO NOW: If you purchased Avantor, Inc. (NYSE: AVTR), shares prior to March 5, 2024 and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/avantor-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased or otherwise acquired Avantor securities between March 5, 2024, and October 28, 2025, you can participate in the class action. $AVTR #Avantor

DexCom, Inc. (NASDAQ: DXCM):

Grabar Law Office is investigating claims on behalf of shareholders of DexCom, Inc. (NASDAQ: DXCM). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased DexCom, Inc. (NASDAQ: DXCM), shares prior to July 26, 2024 and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased or otherwise acquired DexCom securities between July 26, 2024 and September 17, 2025, you can participate in the class action. Please visit https://grabarlaw.com/the-latest/dexcom-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.

WHY? As alleged in an underlying securities fraud class action complaint, DexCom, Inc. (NASDAQ: DXCM), through certain of its officers, made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to the G6 and G7 unauthorized by the U.S. Food and Drug Administration (the "FDA"); (2) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (3) accordingly, Defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (4) Defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; and (5) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm.

WHAT YOU CAN DO NOW: If you purchased DexCom, Inc. (NASDAQ: DXCM), shares prior to July 26, 2024 and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/dexcom-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased or otherwise acquired DexCom securities between July 26, 2024 and September 17, 2025, you can participate in the class action. $DXCM #DexCom

Humana Inc. (NYSE: HUM):

Grabar Law Office is investigating claims on behalf of shareholders of Humana Inc. (NYSE: HUM). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Humana Inc. (NYSE: HUM), shares prior to July 27, 2022, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
Please visit https://grabarlaw.com/the-latest/humana-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.

WHY? As alleged in a recently filed federal securities fraud class action complaint, Humana Inc. (NYSE: HUM), through certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, the Complaint alleges Defendants downplayed pressures on the Company’s adjusted EPS resulting from increased medical costs associated with pent-up demand for healthcare procedures (especially as COVID concerns abated) which, contrary to the Company’s assurances, resulted in increased utilization rates and costs.

WHAT YOU CAN DO NOW: If you purchased Humana Inc. (NYSE: HUM), shares prior to July 27, 2022, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/humana-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #HUM $HUM #Humana

Molina Healthcare, Inc. (NYSE: MOH):

Grabar Law Office is investigating claims on behalf of shareholders of Molina Healthcare, Inc. (NYSE: MOH). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Molina Healthcare, Inc. (NYSE: MOH), shares prior to February 5, 2025 and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased or otherwise acquired Molina securities between February 5, 2025 to July 23, 2025, you can participate in the class action. Please visit https://grabarlaw.com/the-latest/molina-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.

WHY? As alleged in an underlying securities fraud class action complaint, Molina Healthcare, Inc. (NYSE: MOH), through certain of its officers, failed to disclose: (1) material, adverse facts concerning Molina Healthcare's "medical cost trend assumptions"; (2) that Molina Healthcare was experiencing a "dislocation between premium rates and medical cost trend"; (3) that Molina Healthcare's near term growth was dependent on a lack of "utilization of behavioral health, pharmacy, and inpatient and outpatient services"; and (4) as a result, Molina Healthcare's financial guidance for fiscal year 2025 was substantially likely to be cut.

WHAT YOU CAN DO NOW: If you purchased Molina Healthcare, Inc. (NYSE: MOH), shares prior to February 5, 2025 and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/molina-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased or otherwise acquired Molina securities between February 5, 2025 to July 23, 2025, you can participate in the class action. $MOH #Molina

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com